Min Jun1, Rinaldo Bellomo, Alan Cass, Martin Gallagher, Serigne Lo, Joanne Lee. 1. 1The George Institute for Global Health, The University of Sydney, Sydney, NSW, Australia. 2Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG), Carlton, VIC, Australia. 3Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.
Abstract
OBJECTIVES: To explore the relationship between timing of continuous renal replacement therapy commencement and clinical outcomes in critically ill patients with acute kidney injury. The primary outcomes were all-cause mortality at 28 and 90 days. DESIGN: Nested observational cohort study using data from the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study. SETTING:Twenty-three ICUs in Australia and New Zealand. PATIENTS: Four hundred thirty-nine critically ill patients with acute kidney injury Risk, Injury, Failure, Loss, End-stage kidney disease-injury (RIFLE-I) criteria. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The time between RIFLE-I acute kidney injury and randomization in the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study (proxy for continuous renal replacement therapy commencement) was the variable of interest. All baseline variables in the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study were assessed. Multivariable Cox, logistic, and linear regression models were used to assess the independent relationship of time of onset of RIFLE-I acute kidney injury and randomization and patient outcomes. The median time between RIFLE-I acute kidney injury and continuous renal replacement therapy commencement was 17.6 hours (interquartile range, 7.1-46 hr). Based on four groups of continuous renal replacement therapy commencement ([group 1; reference]: < 7.1, [group 2]: ≥ 7.1 to < 17.6, [group 3]: ≥ 17.6 to < 46.0, [group 4]: ≥ 46.0 hr), earlier commencement of continuous renal replacement therapy was not associated with a significantly lower risk of death at 28 days (hazard ratio for group 2: 1.06, 95% CI: 0.62-1.81; p = 0.83; hazard ratio for group 3: 1.23, 95% CI: 0.71-2.12; p = 0.46; hazard ratio for group 4: 1.33, 95% CI: 0.77-2.31; p = 0.31). Similar findings were observed for death at 90 days. CONCLUSIONS: In a subgroup of participants of the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study, earlier commencement of continuous renal replacement therapy relative to RIFLE-I acute kidney injury was not significantly associated with improved survival. Additional studies with larger sample sizes and broader commencement times are warranted.
RCT Entities:
OBJECTIVES: To explore the relationship between timing of continuous renal replacement therapy commencement and clinical outcomes in critically illpatients with acute kidney injury. The primary outcomes were all-cause mortality at 28 and 90 days. DESIGN: Nested observational cohort study using data from the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study. SETTING: Twenty-three ICUs in Australia and New Zealand. PATIENTS: Four hundred thirty-nine critically illpatients with acute kidney injury Risk, Injury, Failure, Loss, End-stage kidney disease-injury (RIFLE-I) criteria. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The time between RIFLE-I acute kidney injury and randomization in the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study (proxy for continuous renal replacement therapy commencement) was the variable of interest. All baseline variables in the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study were assessed. Multivariable Cox, logistic, and linear regression models were used to assess the independent relationship of time of onset of RIFLE-I acute kidney injury and randomization and patient outcomes. The median time between RIFLE-I acute kidney injury and continuous renal replacement therapy commencement was 17.6 hours (interquartile range, 7.1-46 hr). Based on four groups of continuous renal replacement therapy commencement ([group 1; reference]: < 7.1, [group 2]: ≥ 7.1 to < 17.6, [group 3]: ≥ 17.6 to < 46.0, [group 4]: ≥ 46.0 hr), earlier commencement of continuous renal replacement therapy was not associated with a significantly lower risk of death at 28 days (hazard ratio for group 2: 1.06, 95% CI: 0.62-1.81; p = 0.83; hazard ratio for group 3: 1.23, 95% CI: 0.71-2.12; p = 0.46; hazard ratio for group 4: 1.33, 95% CI: 0.77-2.31; p = 0.31). Similar findings were observed for death at 90 days. CONCLUSIONS: In a subgroup of participants of the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study, earlier commencement of continuous renal replacement therapy relative to RIFLE-I acute kidney injury was not significantly associated with improved survival. Additional studies with larger sample sizes and broader commencement times are warranted.
Authors: Mallika L Mendu; George R Ciociolo; Sarah R McLaughlin; Dionne A Graham; Roya Ghazinouri; Siddharth Parmar; Alissa Grossier; Rebecca Rosen; Karl R Laskowski; Leonardo V Riella; Emily S Robinson; David M Charytan; Joseph V Bonventre; Jeffrey O Greenberg; Sushrut S Waikar Journal: Clin J Am Soc Nephrol Date: 2017-01-24 Impact factor: 8.237
Authors: Benjamin T Wierstra; Sameer Kadri; Soha Alomar; Ximena Burbano; Glen W Barrisford; Raymond L C Kao Journal: Crit Care Date: 2016-05-06 Impact factor: 9.097
Authors: Julien Aniort; Ali Ait Hssain; Bruno Pereira; Elisabeth Coupez; Pierre Antoine Pioche; Christophe Leroy; Anne Elisabeth Heng; Bertrand Souweine; Alexandre Lautrette Journal: Crit Care Date: 2016-02-19 Impact factor: 9.097
Authors: Christian Nusshag; Markus A Weigand; Martin Zeier; Christian Morath; Thorsten Brenner Journal: Int J Mol Sci Date: 2017-06-28 Impact factor: 5.923
Authors: Alexander Zarbock; Joachim Gerß; Hugo Van Aken; Andreea Boanta; John A Kellum; Melanie Meersch Journal: Trials Date: 2016-03-18 Impact factor: 2.279